Animal Models Core

动物模型核心

• 批准号: 8070332
• 负责人: Richard Arnold Bowen
• 金额: $ 28.44万
• 依托单位: COLORADO STATE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8070332
• 关键词: Aerosols; Animal Disease Models; Animal Experiments; Animal Model; Animals; Antibiotic Therapy; Area; Autopsy; Biological Assay; Blood specimen; Budgets; Canis familiaris; Clinical; Clinical Chemistry; Clinical Trials; Clinical Trials Design; Collection; Complex; Containment; Data; Data Analyses; Development; Diagnostic; Diagnostic tests; Disease; Domestic Animals; Dose; Emerging Communicable Diseases; Evaluation; Exposure to; Family suidae; Fee Schedules; Fee-for-Service Plans; Funding; Goals; Goat; Government; Hematology; Human; Human Resources; Immune response; Immunologics; Income; Institution; Intervention; Lung; Mission; Modeling; Monitor; Morbidity - disease rate; Mus; National Institute of Allergy and Infectious Disease; Non-Rodent Model; Organ; Pathogenesis; Pathologic; Performance; Pharmaceutical Preparations; Phase I Clinical Trials; Positioning Attribute; Preparation; Reagent; Research; Research Personnel; Resources; Rodent; Rodent Model; Route; Sampling; Serum; Services; Testing; Therapeutic; Therapeutic Agents; Therapy Clinical Trials; Time; Training; United States National Institutes of Health; Vaccine Adjuvant; Vaccines; Viral; Work; Writing; animal rule; antimicrobial drug; base; biodefense; design; good laboratory practice; immunoregulation; mortality; pathogen; product development; programs; research clinical testing; research study; response; tool; vaccine efficacy

The primary mission of the Animal Models Core (Core C) is to conduct animal challenge trials in support of studies by investigators within the RMRCE, at other RCEs and with other governmental, private and academic institutions. These services will be tailored to the needs of the investigator and program, ranging from simple morbidity and mortality experiments, to more complex studies involving aerosol challenges, intense clinical evaluation (i.e. blood sampling over time, telemetric monitoring, hematology), necropsy, histopathologic evaluation and organ pathogen loads. The work will be fee-for-service to investigators, with different fee schedules for RCE and US government investigators versus those from non-RCE academic institutions and commercial entities. In addition to this primary focus on service, Core C personnel will: 1) Assist investigators in the design of appropriate animal experiments, including writing the animal use, select agent and animal budget portions of proposals. This is viewed as a valuable and important service which will ultimately augment program income and contribute to the biodefense effort. 2) Establish new, and enhance existing, rodent models in response to or anticipation of investigator needs. One goal for Year 1 will be to establish, for selected bacterial pathogens, the maximum interval postchallenge at which initiation of high-dose (relevant) antibiotic therapy will allow survival; these data will provide reference points to assist in designing and conducting trials to evaluate therapeutic agents to be applied post-exposure. Another example of enhancing current models will be to characterize the hematologic and clinical chemistry alterations associated with disease pathogenesis; again, this will be valuable in evaluating efficacy of pharmacologic or immunologic interventions. 3) Promote the use of non-rodent models for certain pathogens. Such models could provide large quantities of serum and other samples as reference reagents and to test diagnostic platforms, to provide natural host bases for vaccine and therapeutic trials, and to allow realistic ICU-type monitoring in trials designed to evaluate therapies for human use. Core C is uniquely positioned among RCEs to provide such capabilities. Core C will support all three of the RMRCE Integrated Research Foci on Immunomodulation, Adjuvants and Vaccines (IRF 1), Bacterial Therapeutics (IRF 2), and Viral Therapeutics (IRF 3). Its resources will be utilized by RPs 1.5, 1.6, 1.7, 1.8, 2.3, 2.6, 2.7, 3.3, 3.5 and 3.6.

动物模型核心（核心C）的主要使命是进行动物激发试验，以支持 研究人员在RMRCE内部，在其他RCE以及与其他政府，私人和 学术机构这些服务将根据研究者和项目的需要量身定制， 从简单的发病率和死亡率实验，到涉及气溶胶挑战的更复杂的研究， 密集临床评价（即随时间推移的血样采集、遥测监测、血液学）、尸检， 组织病理学评价和器官病原体负荷。这项工作将对调查人员收取服务费， RCE和美国政府调查人员与非RCE学术人员的费用表不同 机构和商业实体。除了主要关注服务之外，核心C人员还将： 1)协助研究者设计适当的动物实验，包括编写动物用途， 选择代理人和动物预算部分的建议。这被视为一项宝贵而重要的服务 这将最终增加项目收入，并为生物防御工作做出贡献。 2)建立新的和增强现有的啮齿动物模型，以响应或预期研究者的需求。 第1年的一个目标是确定选定细菌病原体的最大攻毒后间隔 开始高剂量（相关）抗生素治疗将允许生存;这些数据将 提供参考点，以协助设计和进行试验，以评估治疗药物， 曝光后应用。增强现有模型的另一个例子是， 与疾病发病机制相关的血液学和临床化学改变;同样，这将是 在评价药物或免疫干预的有效性方面有价值。 3)推广使用非啮齿动物模型检测某些病原体。这种模型可以提供大量的 血清和其他样品作为参考试剂和测试诊断平台，提供天然宿主 疫苗和治疗试验的基础，并允许在试验中进行实际的ICU型监测， 评估人类使用的疗法。Core C在RCE中具有独特的定位，可以提供此类功能。 核心C将支持所有三个RMRCE综合研究重点免疫调节，佐剂和 疫苗（IRF 1）、细菌治疗（IRF 2）和病毒治疗（IRF 3）。其资源将 由RP 1.5、1.6、1.7、1.8、2.3、2.6、2.7、3.3、3.5和3.6使用。